Some studies show that agonists of CB1 and/or CB2 attenuate the carcinogenic potential in lung cancer cells (2, 4–6), and reduce tumor growth in immunodeficient (7) and FVB/N mice (8), however, other studies report the opposite. This evidence concerns the gene CNR2 and lung carcinoma.